C14ORF169在结直肠癌中的表达及对化疗和预后的影响

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (84836 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探索C14ORF169在结直肠癌组织中的表达和对化疗及预后的影响。方法：利用Oncomine数据库分析C14ORF169在结直肠腺瘤、结直肠癌与相应正常组织中的表达水平差异。采用GEO数据库中结直肠癌样本数据集GSE12945和GSE17536分析C14ORF169表达水平与结直肠癌患者临床病理特点及预后的关系。构建C14ORF169高表达和敲减的结直肠癌细胞系，采用CCK-8法检测5-氟尿嘧啶（5-FU）半抑制浓度（IC50）。结果： C14ORF169在结直肠腺瘤和结直肠癌组织中的表达水平均高于相应的正常组织，C14ORF169高表达结直肠癌患者总生存时间和疾病特异性生存时间明显短于低表达患者（P<0.05），C14ORF169高表达与结直肠癌AJCC分期密切相关（P <0.05）。敲减C14ORF169后的结直肠癌细胞对5FU敏感性增加，反之则化疗耐药。结论： C14ORF169在结直肠癌中呈高表达，并与患者化疗耐药及预后不良相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	罗婷怡
	孙伟
	杨庭松
	王士林
	霍钰虎
	韦海鸿
	徐彬

关键词 ： C14ORF169, 结直肠癌, 预后, 化疗

Abstract：Objective: To explore the expression of C14ORF169 in patients with colorectal cancer, and analyze its impact on efficacy of chemotherapy and prognosis. Methods:C14ORF169 differences in expression level of colorectal adenoma, colorectal cancer and corresponding normal tissues were compared using Oncomine database. The correlation of C14ORF169 expression with patients′clinicopathological characteristics and prognosis was analyzed by using the GSE12945 and GSE17536 colorectal cancer datasets downloaded from the gene expression omnibus （GEO） database. The C14ORF169 over expression and knockdown colorectal cancer cell lines were constructed respectively, and the 5-fluorouracil （5-FU） halfmaximal inhibitory concentration （IC50） was detected by using CCK-8 method. Results: The level of C14ORF169 in colorectal adenomas and colorectal cancer tissues were significantly higher than that in normal tissues （P<0.05）. Overall survival and colorectal cancer specific survival of patients with high expression of C14ORF169 were significantly shorter than those with low C14ORF169 expression （P<0.05）. High expression of C14ORF169 was closely related to AJCC advanced stage of colorectal cancer. The sensitivity of colorectal cancer cells to 5FU increased after C14ORF169 knockdown, while C14ORF169 overexpression cell lines showed enhanced chemoresistance. Conclusion: C14ORF169 is highly expressed in colorectal cancer, which is associated with chemotherapy resistance and poor prognosis.

收稿日期: 2020-12-24

基金资助:上海市科委自然科学基金资助项目（18ZR1429600）

通讯作者: 徐彬（通讯作者），副主任医师，副教授，硕士生导师，E-mail: pfdbsxubin@163.com

作者简介: 罗婷怡（1996—），女，硕士研究生

引用本文:

罗婷怡，孙伟，杨庭松，王士林，霍钰虎，韦海鸿，徐彬. C14ORF169在结直肠癌中的表达及对化疗和预后的影响[J]. 江苏大学学报:医学版, 2021, 31(04): 284-289. LUO Tingyi, SUN Wei, YANG Tingsong, WANG Shilin, HUO Yuhu, WEI Haihong, XU Bin.

Expression of C14ORF169 in colorectal cancer and its effect on chemotherapy and prognosis

. Journal of Jiangsu University(Medicine Edition), 2021, 31(04): 284-289.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2021/V31/I04/284

［1］Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2020, 70（4）: 313.

［2］Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality［J］. Gut, 2017, 66（4）: 683-691.

［3］Chen WQ, Zheng RS, Baade PD, et al. Cancer Statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66（2）: 115-132.

［4］Tan E, Gouvas N, Nicholls RJ, et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer［J］. Surg Oncol, 2009, 18（1）: 15-24.

［5］Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018［J］. CA Cancer J Clin, 2018, 68（1）: 7-30.

［6］Choi JE, Bae JS, Kang MJ, et al. Expression of epithelialmesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: clinicopathological significance［J］. Oncol Rep, 2017, 38（3）: 1695-1705.

［7］Eilbracht J, Reichenzeller M, Hergt M, et al. NO66, a highly conserved dual location protein in the nucleolus and in a special type of synchronously replicating chromatin［J］. Mol Biol Cell, 2004, 15（4）: 1816-1832.

［8］Brien GL, Gambero G, O′Connell DJ, et al. Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation［J］. Nat Struct Mol Biol, 2012, 19（12）: 1273-1281.

［9］Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2［J］. Clin Cancer Res, 2008, 14（21）: 6790-6796.

［10］Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144（5）: 646-674.

［11］Baba Y, Murata A, Watanabe M, et al. Clinical implications of the LINE1 methylation levels in patients with gastrointestinal cancer［J］. Surg Today, 2014, 44（10）: 1807-1816.

［12］Suzuki C, Takahashi K, Hayama S, et al. Identification of Mycassociated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer［J］. Mol Cancer Ther, 2007, 6（2）: 542-551.

［13］PiresLuis AS, VieiraCoimbra M, Vieira FQ, et al. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication［J］. Epigenetics, 2015, 10（11）: 1033-1043.

［14］Sinha KM, BagheriYarmand R, Lahiri S, et al. Oncogenic and osteolytic functions of histone demethylase NO66 in castrationresistant prostate cancer［J］. Oncogene, 2019, 38（25）: 5038-5049.

［15］Wang Q, Liu PY, Liu T, et al. The histone demethylase NO66 induces glioma cell proliferation［J］. Anticancer Res, 2019, 39（11）: 6007-6014.

［16］Nishizawa Y, Nishida N, Konno M, et al. Clinical significance of histone demethylase NO66 in invasive colorectal cancer［J］. Ann Surg Oncol, 2017, 24（3）: 841-849.

［17］Camp RL, DolledFilhart M, Rimm DL. Xtile: a new bioinformatics tool for biomarker assessment and outcomebased cutpoint optimization［J］. Clin Cancer Res, 2004, 10（21）: 7252-7259.

［18］SabatesBellver J, Van der Flier LG, de Palo M, et al. Transcriptome profile of human colorectal adenomas［J］. Mol Cancer Res, 2007, 5（12）: 1263-1275.

［19］Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability［J］. PLoS One, 2010, 5（10）: e13091.

［20］Resch A, Langner C. Lymph node staging in colorectal cancer: old controversies and recent advances［J］. World J Gastroenterol, 2013, 19（46）: 8515-8526.

［21］Stewart CL, Warner S, Ito K, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?［J］. Curr Probl Surg, 2018, 55（9）: 330-379.

［22］Woo IS, Jung YH. Metronomic chemotherapy in metastatic colorectal cancer［J］. Cancer Lett, 2017, 400: 319-324.

［23］Fan CW, Chen T, Shang YN, et al. Cancerinitiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies［J］. Cell Death Dis, 2013, 4: e828.

［24］Yaffee P, Osipov A, Tan C, et al. Review of systemic therapies for locally advanced and metastatic rectal cancer［J］. J Gastrointest Oncol, 2015, 6（2）: 185-200.